Reviews Abobotulinumtoxin A Injection


No reviews yet.

Dysport Drug Description
DYSPORT™
(abobotulinumtoxinA) for Injection

Distant Spread of Toxin Effect
Postmarketing reports indicate that the effects of DYSPORT™ and all botulinum
toxin products may spread from the area of injection to produce symptoms consistent
with botulinum toxin effects. These may include asthenia, generalized muscle
weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria,
urinary incontinence and breathing difficulties. These symptoms have been reported
hours to weeks after injection. Swallowing and breathing difficulties can be
life threatening and there have been reports of death. The risk of symptoms
is probably greatest in children treated for spasticity but symptoms can also
occur in adults treated for spasticity and other conditions, particularly in
those patients who have underlying conditions that would predispose them to
these symptoms. In unapproved uses, including spasticity in children and adults,
and in approved indications, cases of spread of effect have been reported at
doses comparable to those used to treat cervical dystonia and at lower doses.

DRUG DESCRIPTION
Botulinum toxin type A, the active ingredient in DYSPORT™ (abobotulinumtoxinA),
is a purifed neurotoxin type A complex produced by fermentation of the bacterium
Clostridium botulinumtype A, Hall Strain. It is purifed from the culture
supernatant by a series of precipitation, dialysis, and chromatography steps.
The neurotoxin complex is composed of the neurotoxin, hemagglutinin proteins
and non-toxin non-hemagglutinin protein.
DYSPORT™ is supplied in a single-use, sterile vial for reconstitution
intended for intramuscular injection. Each vial contains 500 or 300 Units of
lyophilized abobotulinumtoxinA, 125 micrograms human serum albumin and 2.5 mg
lactose. DYSPORT™ may contain trace amounts of cow's milk proteins [see
CONTRAINDICATIONS].
One unit of DYSPORT™ corresponds to the calculated median lethal intraperitoneal
dose (LD50) in mice. The method for performing the assay is specifc to Ipsen's
product DYSPORT™ Due to differences in specifc details such as vehicle,
dilution scheme and laboratory protocols for various mouse LD50 assays, Units
of biological activity of DYSPORT™ are not interchangeable with Units
of any other botulinum toxin or any toxin assessed with any other specifc assay
method [see Dosage Forms and Strengths].
Last reviewed on RxList: 5/22/2009




Dysport Drug Description
DYSPORT™
(abobotulinumtoxinA) for Injection

Distant Spread of Toxin Effect
Postmarketing reports indicate that the effects of DYSPORT™ and all botulinum
toxin products may spread from the area of injection to produce symptoms consistent
with botulinum toxin effects. These may include asthenia, generalized muscle
weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria,
urinary incontinence and breathing difficulties. These symptoms have been reported
hours to weeks after injection. Swallowing and breathing difficulties can be
life threatening and there have been reports of death. The risk of symptoms
is probably greatest in children treated for spasticity but symptoms can also
occur in adults treated for spasticity and other conditions, particularly in
those patients who have underlying conditions that would predispose them to
these symptoms. In unapproved uses, including spasticity in children and adults,
and in approved indications, cases of spread of effect have been reported at
doses comparable to those used to treat cervical dystonia and at lower doses.

DRUG DESCRIPTION
Botulinum toxin type A, the active ingredient in DYSPORT™ (abobotulinumtoxinA),
is a purifed neurotoxin type A complex produced by fermentation of the bacterium
Clostridium botulinumtype A, Hall Strain. It is purifed from the culture
supernatant by a series of precipitation, dialysis, and chromatography steps.
The neurotoxin complex is composed of the neurotoxin, hemagglutinin proteins
and non-toxin non-hemagglutinin protein.
DYSPORT™ is supplied in a single-use, sterile vial for reconstitution
intended for intramuscular injection. Each vial contains 500 or 300 Units of
lyophilized abobotulinumtoxinA, 125 micrograms human serum albumin and 2.5 mg
lactose. DYSPORT™ may contain trace amounts of cow's milk proteins [see
CONTRAINDICATIONS].
One unit of DYSPORT™ corresponds to the calculated median lethal intraperitoneal
dose (LD50) in mice. The method for performing the assay is specifc to Ipsen's
product DYSPORT™ Due to differences in specifc details such as vehicle,
dilution scheme and laboratory protocols for various mouse LD50 assays, Units
of biological activity of DYSPORT™ are not interchangeable with Units
of any other botulinum toxin or any toxin assessed with any other specifc assay
method [see Dosage Forms and Strengths].
Last reviewed on RxList: 5/22/2009




Dysport Drug Description
DYSPORT™
(abobotulinumtoxinA) for Injection

Distant Spread of Toxin Effect
Postmarketing reports indicate that the effects of DYSPORT™ and all botulinum
toxin products may spread from the area of injection to produce symptoms consistent
with botulinum toxin effects. These may include asthenia, generalized muscle
weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria,
urinary incontinence and breathing difficulties. These symptoms have been reported
hours to weeks after injection. Swallowing and breathing difficulties can be
life threatening and there have been reports of death. The risk of symptoms
is probably greatest in children treated for spasticity but symptoms can also
occur in adults treated for spasticity and other conditions, particularly in
those patients who have underlying conditions that would predispose them to
these symptoms. In unapproved uses, including spasticity in children and adults,
and in approved indications, cases of spread of effect have been reported at
doses comparable to those used to treat cervical dystonia and at lower doses.

DRUG DESCRIPTION
Botulinum toxin type A, the active ingredient in DYSPORT™ (abobotulinumtoxinA),
is a purifed neurotoxin type A complex produced by fermentation of the bacterium
Clostridium botulinumtype A, Hall Strain. It is purifed from the culture
supernatant by a series of precipitation, dialysis, and chromatography steps.
The neurotoxin complex is composed of the neurotoxin, hemagglutinin proteins
and non-toxin non-hemagglutinin protein.
DYSPORT™ is supplied in a single-use, sterile vial for reconstitution
intended for intramuscular injection. Each vial contains 500 or 300 Units of
lyophilized abobotulinumtoxinA, 125 micrograms human serum albumin and 2.5 mg
lactose. DYSPORT™ may contain trace amounts of cow's milk proteins [see
CONTRAINDICATIONS].
One unit of DYSPORT™ corresponds to the calculated median lethal intraperitoneal
dose (LD50) in mice. The method for performing the assay is specifc to Ipsen's
product DYSPORT™ Due to differences in specifc details such as vehicle,
dilution scheme and laboratory protocols for various mouse LD50 assays, Units
of biological activity of DYSPORT™ are not interchangeable with Units
of any other botulinum toxin or any toxin assessed with any other specifc assay
method [see Dosage Forms and Strengths].
Last reviewed on RxList: 5/22/2009




Dysport Drug Description
DYSPORT™
(abobotulinumtoxinA) for Injection

Distant Spread of Toxin Effect
Postmarketing reports indicate that the effects of DYSPORT™ and all botulinum
toxin products may spread from the area of injection to produce symptoms consistent
with botulinum toxin effects. These may include asthenia, generalized muscle
weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria,
urinary incontinence and breathing difficulties. These symptoms have been reported
hours to weeks after injection. Swallowing and breathing difficulties can be
life threatening and there have been reports of death. The risk of symptoms
is probably greatest in children treated for spasticity but symptoms can also
occur in adults treated for spasticity and other conditions, particularly in
those patients who have underlying conditions that would predispose them to
these symptoms. In unapproved uses, including spasticity in children and adults,
and in approved indications, cases of spread of effect have been reported at
doses comparable to those used to treat cervical dystonia and at lower doses.

DRUG DESCRIPTION
Botulinum toxin type A, the active ingredient in DYSPORT™ (abobotulinumtoxinA),
is a purifed neurotoxin type A complex produced by fermentation of the bacterium
Clostridium botulinumtype A, Hall Strain. It is purifed from the culture
supernatant by a series of precipitation, dialysis, and chromatography steps.
The neurotoxin complex is composed of the neurotoxin, hemagglutinin proteins
and non-toxin non-hemagglutinin protein.
DYSPORT™ is supplied in a single-use, sterile vial for reconstitution
intended for intramuscular injection. Each vial contains 500 or 300 Units of
lyophilized abobotulinumtoxinA, 125 micrograms human serum albumin and 2.5 mg
lactose. DYSPORT™ may contain trace amounts of cow's milk proteins [see
CONTRAINDICATIONS].
One unit of DYSPORT™ corresponds to the calculated median lethal intraperitoneal
dose (LD50) in mice. The method for performing the assay is specifc to Ipsen's
product DYSPORT™ Due to differences in specifc details such as vehicle,
dilution scheme and laboratory protocols for various mouse LD50 assays, Units
of biological activity of DYSPORT™ are not interchangeable with Units
of any other botulinum toxin or any toxin assessed with any other specifc assay
method [see Dosage Forms and Strengths].
Last reviewed on RxList: 5/22/2009




Dysport Drug Description
DYSPORT™
(abobotulinumtoxinA) for Injection

Distant Spread of Toxin Effect
Postmarketing reports indicate that the effects of DYSPORT™ and all botulinum
toxin products may spread from the area of injection to produce symptoms consistent
with botulinum toxin effects. These may include asthenia, generalized muscle
weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria,
urinary incontinence and breathing difficulties. These symptoms have been reported
hours to weeks after injection. Swallowing and breathing difficulties can be
life threatening and there have been reports of death. The risk of symptoms
is probably greatest in children treated for spasticity but symptoms can also
occur in adults treated for spasticity and other conditions, particularly in
those patients who have underlying conditions that would predispose them to
these symptoms. In unapproved uses, including spasticity in children and adults,
and in approved indications, cases of spread of effect have been reported at
doses comparable to those used to treat cervical dystonia and at lower doses.

DRUG DESCRIPTION
Botulinum toxin type A, the active ingredient in DYSPORT™ (abobotulinumtoxinA),
is a purifed neurotoxin type A complex produced by fermentation of the bacterium
Clostridium botulinumtype A, Hall Strain. It is purifed from the culture
supernatant by a series of precipitation, dialysis, and chromatography steps.
The neurotoxin complex is composed of the neurotoxin, hemagglutinin proteins
and non-toxin non-hemagglutinin protein.
DYSPORT™ is supplied in a single-use, sterile vial for reconstitution
intended for intramuscular injection. Each vial contains 500 or 300 Units of
lyophilized abobotulinumtoxinA, 125 micrograms human serum albumin and 2.5 mg
lactose. DYSPORT™ may contain trace amounts of cow's milk proteins [see
CONTRAINDICATIONS].
One unit of DYSPORT™ corresponds to the calculated median lethal intraperitoneal
dose (LD50) in mice. The method for performing the assay is specifc to Ipsen's
product DYSPORT™ Due to differences in specifc details such as vehicle,
dilution scheme and laboratory protocols for various mouse LD50 assays, Units
of biological activity of DYSPORT™ are not interchangeable with Units
of any other botulinum toxin or any toxin assessed with any other specifc assay
method [see Dosage Forms and Strengths].
Last reviewed on RxList: 5/22/2009





Other reviews about Abobotulinumtoxin A Injection on wordpress

FDA Requires Boxed Warning for All Botulinum Toxin Products
  by thassodotcom
June 10, 2009 - From a todays' press release by the FDA, we learn the following concerning botulinum toxin products: Prompted by reports of serious adverse events, the American […]



Other reviews about Abobotulinumtoxin A Injection on web:

Learn about the prescription medication Dysport (Abobotulinumtoxin A Injection), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Dysport (Abobotulinumtoxin A Injection) Drug Information: Uses ...


Dysport (Abobotulinumtoxin A Injection Vials) by ABC online pharmacy. Offers the most competitive prices on Dysport (Abobotulinumtoxin A Injection Vials). The most trusted Dysport ... Buy Dysport (Abobotulinumtoxin A Injection Vials) at Online Canada ...


Dysport® (abobotulinumtoxin A for injection): Wrinkle Removal in Wichita, Kansas. Innovative Vein introduces Dysport – a new kind of wrinkle treatment in Wichita, Kansas. Dysport Injections in Wichita, KS | Kansas Wrinkle Removal


,Browse for prescription Rx drugs and OTC medications from an inventory of over 6000 drugs all at wholesale prices! Dysport (Abobotulinumtoxin A Injection Vials) : Online Pharmacy ...


,Browse for prescription Rx drugs and OTC medications from an inventory of over 6000 drugs all at wholesale prices! Buy Dysport (Abobotulinumtoxin A Injection Vials) : Canadian ...


... Dysport Brand of Botulinum Toxin Type A): Aetna considers abobotulinumtoxin A (Dysport ... Injection of BTX- A reduces pressure in the pelvic floor muscles more than placebo; it ... Botulinum Toxin


NEW Dysport (abobotulinumtoxin A) for smoothing facial wrinkles, now available at all three ... examination of your eyes is made in order to decide the most effective injection sites Botox Cosmetic, Cosmetic Surgery, Hawaii


Dysport (abobotulinumtoxin A) ... The most common side effects were nose and throat irritation, headache, injection site ... Dysport (abobotulinumtoxin A) Handout - Doctor recommended review


Abobotulinumtoxin A was approved for marketing on Wednesday, said Ellis F. Unger, acting ... about the risk of toxin-related neurologic effects developing distant to the injection ... News Article : Botulinum Toxin Products Get Boxed Warning ...


Abobotulinumtoxin A Injection (Dysport) Abraxane (Albumin-bound Paclitaxel) Acamprosate Calcium (Campral) Acanya Gel (Clindamycin Phosphate 1.2% and Benzoyl Peroxide 2.5%) Drugs A-Z List - A on RxList





Featured Reviews

Reviews Ethambutol

Myambutol Drug Description MYAMBUTOL (ethambutol hcl) Tablets DRUG DESCRIPTION What are the possible side effects of ethambutol (Myambutol)? If you experience any of the following serious side effects, stop taking ethambutol and...
Read More  |  Review This
Reviews Estradiol Transdermal System

Vivelle-Dot Drug Description Vivelle-Dot® (estradiol transdermal system) Continuous delivery for twice-weekly application ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens...
Read More  |  Review This
Reviews Ketamine HCl

Ketamine Hydrochloride Drug Description Ketamine Hydrochloride Injection, USP SPECIAL NOTE EMERGENCE REACTIONS HAVE OCCURRED IN APPROXIMATELY 12 PERCENT OF PATIENTS. THE PSYCHOLOGICAL MANIFESTATIONS VARY IN SEVERITY BETWEEN PLEASANT...
Read More  |  Review This
Reviews Medroxyprogesterone

Depo Provera Drug Description DEPO-PROVERA (medroxyprogesterone acetate), Contraceptive Injection Physician Information Women who use Depo-Provera Contraceptive Injection may lose significant bone mineral density. Bone loss is greater...
Read More  |  Review This
Reviews Flurbiprofen

Ansaid Drug Description Ansaid® (flurbiprofen) Tablets, USP 50 mg and 100 mg Cardiovascular Risk NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....